offers one-on-one support throughout the treatment journey.* From starting treatment to navigating insurance, A•S•A•P can help your patients stay on track.
*A•S•A•P helps provide patient support services to eligible patients who have been prescribed YUVIWEL for its approved indication.
If commercially insured and eligible, A•S•A•P can help your patient obtain treatment through the Co-Pay Program.
Patients are NOT eligible if they:
The Ascendis Patient Assistance Program can help provide free treatment if your patient meets the eligibility requirements, does not have insurance or is underinsured, or is unable to afford treatment.
Questions? Call 1-844-442-7236 and select option 3.
Patient support starts with enrollment. Here’s a guide to help get your patients started with A•S•A•P and YUVIWEL.
Get started by enrolling your patient for support today.
Help your patients complete and submit the Patient Consent Form.
You can also download and fax the completed Enrollment Form and Patient Consent Form to 1-888-436-0193.
Interested in learning more about YUVIWEL for your patients with achondroplasia?
Please fill out the form below for updates and resources.
Transient decreases in blood pressure have been reported with a once-daily C-type natriuretic peptide (CNP) analog. Subjects with hemodynamically significant cardiovascular disease were excluded from participation in YUVIWEL clinical trials. Advise patients to contact their healthcare provider if they experience symptoms of decreased blood pressure (eg, dizziness, fatigue, and/or nausea) while being treated with YUVIWEL.
YUVIWEL is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses.
This indication is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Transient decreases in blood pressure have been reported with a once-daily C-type natriuretic peptide (CNP) analog. Subjects with hemodynamically significant cardiovascular disease were excluded from participation in YUVIWEL clinical trials. Advise patients to contact their healthcare provider if they experience symptoms of decreased blood pressure (eg, dizziness, fatigue, and/or nausea) while being treated with YUVIWEL.
The most common adverse reactions (≥5%) are vomiting, injection site reaction, pain in extremity, and nausea.
There are no available data on the use of YUVIWEL in pregnant women, or data on the presence of YUVIWEL in human milk, the potential effects on milk production or the breastfed infant. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for YUVIWEL and any potential adverse effects on the breastfed infant from YUVIWEL or from the underlying maternal condition.
YUVIWEL is not recommended for patients with moderate or severe renal impairment.
You are encouraged to report side effects to FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Ascendis Pharma at 1-844-442-7236.
Please see full Prescribing Information for YUVIWEL.
FDA=Food and Drug Administration.